Address
Skyline Ventures
263 Tresser Boulevard
One Stamford Plaza, Suite 902
Stamford, CT 06901
United States
Phone
Website
Recent investment activity
KANDO id: 31560
Corporate information
Registration country
Company type
Life Sciences venture capital firmFunding rounds
Top investment portfolio themes
Actual initial investment stage
N/A (1)
Investment activity status
Active investor
Selected investments
Displaying 26 - 37 of 37Company | Profile | Country | Date | Funding | ||
---|---|---|---|---|---|---|
Tetraphase Pharmaceuticals Inc | A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. | Series A | ||||
Tetraphase Pharmaceuticals Inc | A biopharmaceutical company utilizing a synthetic chemistry technology platform to treat drug-resistant bacterial infections. | Series B | ||||
Tolerx Inc | Developer of a novel therapies focusing on modulating T-cell activities for treating autoimmune diseases, diabetes, and cancer. | N/A | ||||
Amgen Inc | Series C | |||||
Calypso Medical Technologies Inc | A medical device company developing innovative tools and therapies for the oncology marketa advancing cancer radiation treatment. | Series E led the round | ||||
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series C | ||||
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series B | ||||
Concert Pharmaceuticals Inc | A biotechnology company creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. | Series A | ||||
Hansen Medical Inc | Hansen Medical makes an electromechanical robotic system. | Series C | ||||
InteKrin Therapeutics Inc | Biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders.. | Series C | ||||
Sirtris Pharmaceuticals Inc | Series C | |||||
XenoPort Inc | N/A Initial investment |